Myeloma Precursor Disease among WTC responders
WTC 响应者中的骨髓瘤前驱疾病
基本信息
- 批准号:10064268
- 负责人:
- 金额:$ 49.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Project Summary/Abstract
Hazardous materials including known and suspected carcinogens, were present at the World Trade Center
(WTC) disaster site.1,2 For example, some carcinogens present at the WTC disaster site have been found to be
associated with multiple myeloma and its precursor disease, in veterans of the Vietnam War exposed to Agent
Orange. Recently, in a screening study for multiple myeloma precursor disease, the prevalence of overall
monoclonal gammopathy of undetermined significance (MGUS) among WTC-exposed white male firefighters
was significantly greater than the general population (risk ratio [RR]=1.76; 95% CI=1.34, 2.29).3 This
association was particularly elevated in light-chain MGUS (RR=3.13; 95% CI=1.99, 4.93).3 Additionally, WTC-
exposed firefighters compared with the general population had higher proportions with light chain disease and
CD20 positive plasma cells, which are typically associated with poorer prognoses.3
In an effort to broaden current knowledge of the relationship between WTC exposure, MGUS and multiple
myeloma, we propose a collaborative effort between the Fire Department of the City of New York (FDNY) and
General Responder Cohort at Stony Brook University (GRC-SBU) to conduct sensitive immunophenotyping to
detect MGUS by screening non-FDNY rescue-recovery workers and comparing results to determine if there
are differences between the two responder cohorts. We will then pool data from the two cohorts to generate a
global prevalence estimate for the entire WTC-exposed rescue-recovery population. By expanding MGUS
screening beyond white male firefighters, we will assess whether the association between WTC exposure and
MGUS applies to a more demographically heterogeneous population. Additionally, this will provide us with a
better understanding of the disease pathogenesis in participants exposed to the WTC disaster. Finally, an early
workup of MGUS can provide potentially disease-modifying therapeutic interventions. This study will allow us
to realize the NIOSH WTC Health Program's “Research to Care” translational model.
Specifically we aim to 1) To analyze the precursor state of multiple myeloma, MGUS, among WTC-exposed
GRC-SBU participants and to compare the prevalence among white males to WTC-exposed white male FDNY
firefighters; and 2) To compare the prevalence of MGUS among the combined WTC-exposed responder
cohorts (both FDNY and GRC-SBU) to published estimates in population-based studies.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Carl Ola Landgren其他文献
Carl Ola Landgren的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Carl Ola Landgren', 18)}}的其他基金
CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS
CD38 靶向骨髓瘤免疫宠物:临床应用 2 期试验
- 批准号:
10286324 - 财政年份:2020
- 资助金额:
$ 49.26万 - 项目类别:
CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS
CD38 靶向骨髓瘤免疫宠物:临床应用 2 期试验
- 批准号:
10684341 - 财政年份:2020
- 资助金额:
$ 49.26万 - 项目类别:
CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS
CD38 靶向骨髓瘤免疫宠物:临床应用 2 期试验
- 批准号:
10162562 - 财政年份:2020
- 资助金额:
$ 49.26万 - 项目类别:
CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS
CD38 靶向骨髓瘤免疫宠物:临床应用 2 期试验
- 批准号:
10756584 - 财政年份:2020
- 资助金额:
$ 49.26万 - 项目类别:
Molecular Characterization of Multiple Myeloma Ethnic Disparity
多发性骨髓瘤种族差异的分子特征
- 批准号:
9137629 - 财政年份:2015
- 资助金额:
$ 49.26万 - 项目类别:
相似国自然基金
有耗色散介质中Precursor波形成机理及其用于穿透成像的研究
- 批准号:40771133
- 批准年份:2007
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Ultralong-term single-molecule imaging of amyloid precursor protein (APP) processing in Alzheimer's disease
阿尔茨海默病中淀粉样前体蛋白(APP)加工的超长期单分子成像
- 批准号:
10738516 - 财政年份:2022
- 资助金额:
$ 49.26万 - 项目类别:
The amyloid precursor protein intracellular domain is an effector molecule of metaplasticity - implications for the regulation of synaptic plasticity in Alzheimer disease.
淀粉样蛋白前体蛋白胞内结构域是化塑性的效应分子——对阿尔茨海默病突触可塑性的调节具有影响。
- 批准号:
447315 - 财政年份:2021
- 资助金额:
$ 49.26万 - 项目类别:
Operating Grants
The amyloid precursor protein intracellular domain is an effector molecule of metaplasticity - implications for the regulation of synaptic plasticity in Alzheimer disease.
淀粉样蛋白前体蛋白胞内结构域是化塑性的效应分子——对阿尔茨海默病突触可塑性的调节具有影响。
- 批准号:
451410 - 财政年份:2021
- 资助金额:
$ 49.26万 - 项目类别:
Operating Grants
Repurposing Metformin for the Prevention of Disease Progression in Precursor Multiple Myeloma
重新利用二甲双胍预防前体多发性骨髓瘤的疾病进展
- 批准号:
10471280 - 财政年份:2020
- 资助金额:
$ 49.26万 - 项目类别:
Repurposing Metformin for the Prevention of Disease Progression in Precursor Multiple Myeloma
重新利用二甲双胍预防前体多发性骨髓瘤的疾病进展
- 批准号:
10039293 - 财政年份:2020
- 资助金额:
$ 49.26万 - 项目类别:
Ultralong-term single-molecule imaging of amyloid precursor protein (APP) processing in Alzheimer's disease
阿尔茨海默病中淀粉样前体蛋白(APP)加工的超长期单分子成像
- 批准号:
10078232 - 财政年份:2020
- 资助金额:
$ 49.26万 - 项目类别:
Repurposing Metformin for the Prevention of Disease Progression in Precursor Multiple Myeloma
重新利用二甲双胍预防前体多发性骨髓瘤的疾病进展
- 批准号:
10249288 - 财政年份:2020
- 资助金额:
$ 49.26万 - 项目类别:
Novel role of TFEB in ADAM10 potentiation and proliferation of neural precursor cells relevant to Alzheimer's disease
TFEB 在 ADAM10 增强和与阿尔茨海默病相关的神经前体细胞增殖中的新作用
- 批准号:
9981582 - 财政年份:2019
- 资助金额:
$ 49.26万 - 项目类别:
The intersection of Alzheimer’s disease and ribosome biogenesis through Amyloid Beta Precursor Protein Binding Family B Member 1 (APBB1; FE65)
阿尔茨海默病和核糖体生物发生通过淀粉样β前体蛋白结合家族 B 成员 1 (APBB1; FE65) 的交叉
- 批准号:
9469760 - 财政年份:2018
- 资助金额:
$ 49.26万 - 项目类别:
Molecular evolution of myeloma from precursor through to relapsed disease
骨髓瘤从前驱疾病到复发疾病的分子进化
- 批准号:
382711 - 财政年份:2018
- 资助金额:
$ 49.26万 - 项目类别:
Operating Grants